Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
HOUSTON, May 04, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 11, 2017 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2017, and to provide a business overview.
To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time, and refer to conference ID 11686674. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information: Investors Will O’Connor Stern Investor Relations 212-362-1200 [email protected] Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
